Inhibition of cardiac allograft vasculopathy by sirolimus and mycofenolate: Asymmetric dimethyl arginine as a potential therapeutic target

被引：1
|
作者：
Potena, L. [1 ,2 ]
Fearon, W. [1 ]
Sydow, K. [1 ]
Holweg, C. [1 ]
Luikart, H. [1 ]
Mocarski, E. [1 ]
Valantine, H. [1 ]
Cooke, J. [1 ]
机构：
[1] Stanford Univ, Stanford, CA 94305 USA
[2] Univ Bologna, Bologna, Italy
来源：
JOURNAL OF HEART AND LUNG TRANSPLANTATION | 2006年 / 25卷 / 02期
关键词：
D O I：
10.1016/j.healun.2005.11.169
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
162
引用
收藏
页码：S100 / S100
页数：1
相关论文
共 50 条
  • [1] Asymmetric dimethylarginine and cardiac allograft vasculopathy progression: Modulation by sirolimus
    Potena, Luciano
    Fearon, William F.
    Sydow, Karsten
    Holweg, Cecile
    Luikart, Helen
    Chin, Clifford
    Weisshaar, Dana
    Mocarski, Edward S.
    Lewis, David B.
    Valantine, Hannah A.
    Cooke, John P.
    TRANSPLANTATION, 2008, 85 (06) : 827 - 833
  • [2] Role of Transient Receptor Potential Channels in Heart Transplantation: A Potential Novel Therapeutic Target for Cardiac Allograft Vasculopathy
    Ma, Shuo
    Jiang, Yue
    Huang, Weiting
    Li, Xintao
    Li, Shuzhuang
    MEDICAL SCIENCE MONITOR, 2017, 23 : 2340 - 2347
  • [3] Hedgehog signalling in allograft vasculopathy: a new therapeutic target?
    Rowell, Jasmine
    Lau, Ching-In
    Yanez, Diana C.
    Zhang, Eden
    Crompton, Tessa
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2023, 44 (09) : 558 - 560
  • [4] Hyperlipidemia from Sirolimus: Adverse Impact on Development of Cardiac Allograft Vasculopathy
    Patel, J.
    Kittleson, M.
    Kawano, M.
    Goldstein, Z.
    Rafiei, M.
    Moradzadeh, A.
    Azarbal, B.
    Czer, L.
    Kass, R.
    Kobashigawa, J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2011, 30 (04): : S12 - S12
  • [5] Angiographic regression of cardiac allograft vasculopathy after introducing sirolimus immunosuppression
    Ruygrok, PN
    Webber, B
    Faddy, S
    Muller, DW
    Keogh, A
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2003, 22 (11): : 1276 - 1279
  • [6] T cell costimulation in the development of cardiac allograft vasculopathy - Potential targets for therapeutic interventions
    Isobe, Mitsuaki
    Kosuge, Hisanori
    Suzuki, Jun-ichi
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (07) : 1447 - 1456
  • [7] Sirolimus as primary immunosuppression is effective in attenuating progression of cardiac-allograft vasculopathy
    Joren C Madsen
    Nature Clinical Practice Cardiovascular Medicine, 2008, 5 : 300 - 301
  • [8] Sirolimus-eluting stent fractures leading to restenosis in cardiac allograft vasculopathy
    Cilingiroglu, Mehmet
    Chilakapati, Venkata
    Dunlap, Stephanie
    Leesar, Massoud A.
    CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2010, 11 (02) : 120 - 123
  • [9] Sirolimus as primary immunosuppression is effective in attenuating progression of cardiac-allograft vasculopathy
    Madsen, Joren C.
    NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2008, 5 (06): : 300 - 301
  • [10] Nitric oxide and endothelin in the development of cardiac allograft vasculopathy.: Potential targets for therapeutic interventions
    Liu, ZQ
    Wildhirt, SM
    Weismüller, S
    Schulze, C
    Conrad, N
    Reichart, B
    ATHEROSCLEROSIS, 1998, 140 (01) : 1 - 14
12345